Trevi Therapeutics, Inc. Discusses Commercialization for Its Investigational Therapy, Haduvio, with The Stock Day Podcast

The Stock Day Podcast welcomed Trevi Therapeutics, Inc. (TRVI) (“the Company”), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF). President and CEO of the Company, Jennifer Good, joined Stock Day host Sever Copley.